Mount Sinai researchers are exploring the finding that certain proteins produced by patients with mild to moderate eosinophilic asthma downregulate the angiotensin-converting enzyme 2 receptor that allows SARS-CoV-2 entry to airway cells, resulting in a less severe course of COVID-19. The finding could lead to new therapeutic approaches.